Open Menu Close Menu Open Search Close Search

Dr. Sheldon Rowan is Scientist II on the Nutrition and Vision Team at the HNRCA. He researches the role of dietary patterns in the development of age-related macular degeneration (AMD) and its relationship to aging, metabolism and the gut microbiome; novel biomarkers for AMD; and the developmental and biochemical bases of cataract formation. He demonstrated that mice fed diets high in low-quality carbohydrates (high glycemic diets) develop features relevant to age-related macular degeneration and that shifting to a high-quality carbohydrate diet could prevent the development of this debilitating disease. He discovered that this dietary mechanism involved gut microbiota and that eye health could be directly affected by changing the gut microbiome. He is an Assistant Professor of Ophthalmology at Tufts University School of Medicine and an Assistant Professor of Nutrition at the Friedman School for Nutrition and Science Policy. Dr. Rowan is a member of the American Society for Nutrition and the Association for Research in Vision and Ophthalmology. He received a Bachelor of Science degree from McMaster University in Canada and his Ph.D. from Harvard University. He completed a postdoctoral fellowship at Brigham and Women’s Hospital.

Ph.D., Genetics, Harvard University
B.Sc., Molecular Biology and Biotechnology, McMaster University, Canada

Academic Appointments
Assistant Professor of Ophthalmology, School of Graduate Biomedical Sciences at Tufts University

Assistant Professor of Nutrition, Friedman School of Nutrition and Science Policy at Tufts University

Current Research Projects
 USDA-ARS: Vision, Aging, and Nutrition
BrightFocus Foundation: Role of the gut microbiota in a mouse model of AMD
HNRCA Pilot Grant: Role of gut barrier integrity in maintaining ocular, muscle, and intestinal health during aging
NIH-NEI: Mechanistically linking AMD, glycemic index and protein homeostasis
USDA/AFRI/NIFA: Optimizing dietary carbohydrates to diminish inflammation and age-related eye disease
Thome Memorial Foundation: Repurposing FDA approved drugs to limit AMD